oral drug, covalent inhibitor of KRASG12C

effective in KRASG12C-mutated cancer models

SBDD utilizing KRAS proto-oncogene, GTPase

British Journal of Cancer

Astellas Pharma Inc.

Chemical structure of molecule ASP2453 Astellas KRASG12C covalent inhibitor

3.      The Astellas KRASG12C covalent inhibitor, ASP2453, is an oral molecule with activity in preclinical mouse models of KRASG12C-mutated cancer at lower doses than sotorasib (AMG 510). Several KRAS inhibitors have…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: